Physician profile
Samuel Grimm
NPI 1841223674
$367.07
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $107 · 2021: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.40 | 2019-2021 | |
| Renovia INC | $49.29 | 2021 | |
| Therapeuticsmd, INC. | $48.66 | 2019-2020 | |
| Hologic Sales and Service, LLC | $45.72 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $43.11 | 2019 | |
| Lupin INC. | $42.44 | 2020 | |
| Daiichi Sankyo INC. | $16.20 | 2020 | |
| Coopersurgical, INC. | $11.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.